Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug candidate Trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.

OUR TECHNOLOGY

Lead drug
candidate, Trans sodium
crocetinate (TSC)

We are developing our lead product, TSC, to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.

Learn more

News

Latest press releases, announcements, and more.

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

 Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

 Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

 Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

 Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

 Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

 Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

 Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

 Diffusion Pharmaceuticals Completes Dosing in Altitude Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

News Releases
Back to top